Soluble TNF-Like weak inducer of apoptosis as a new marker in preeclampsia: A pilot clinical study

Basit Öğe Kaydı
dc.contributor.authorYıldırım Kayaoğlu, Zeynep
dc.contributor.authorSümnü, Abdullah
dc.contributor.authorBademler, Neslihan
dc.contributor.authorKılıç, Elif
dc.contributor.authorSümnü, Gülay
dc.contributor.authorKaradağ, Serhat
dc.contributor.authorGürsü, Meltem
dc.contributor.authorÖzel, Ayşegül
dc.contributor.authorBatmaz, Gonca
dc.contributor.authorAteş, Seda
dc.contributor.authorDane, Banu
dc.contributor.authorÖztürk, Savaş
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:51:51Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:51:51Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nöroloji Ana Bilim Dalı
dc.descriptionWOS: 000371089200001
dc.descriptionPubMed ID: 26989294
dc.description.abstractIntroduction. All findings of preeclampsia appear as the clinical consequences of diffuse endothelial dysfunction. Soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) was recently introduced as a TNF related cytokine in various inflammatory and noninflammatory disorders. sTWEAK was found to be related to endothelial dysfunction in patients with chronic kidney disease. In our study we aimed to compare sTWEAK levels in women with preeclampsia to corresponding levels in a healthy pregnant control group. Materials and Methods. The study was undertaken with 33 patients with preeclampsia and 33 normal pregnant women. The concentration of sTWEAK in serum was calculated with an enzyme linked immunosorbent assay (ELISA) kit. Results. Serum creatinine, uric acid, LDH levels, and uPCR were significantly higher in the patient group compared to the control group. sTWEAK levels were significantly lower in preeclamptic patients (332 +/- 144 pg/mL) than in control subjects (412 +/- 166 pg/mL) (p = 0.04). Discussion. Our study demonstrates that sTWEAK is decreased in patients with preeclampsia compared to healthy pregnant women. There is a need for further studies to identify the role of sTWEAK in the pathogenesis of preeclampsia and to determine whether it can be regarded as a predictor of the development of preeclampsia.
dc.identifier.citationYıldırım Kayaoğlu, Z., Sümnü, A., Bademler, N., Kılıç, E., Sümnü, G., Karadağ, S. ... Öztürk, S. (2016). Soluble TNF-Like weak inducer of apoptosis as a new marker in preeclampsia: A pilot clinical study. Disease Markers. https://dx.doi.org/10.1155/2016/5930589
dc.identifier.doi10.1155/2016/5930589
dc.identifier.issn0278-0240
dc.identifier.issn1875-8630
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://dx.doi.org/10.1155/2016/5930589
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2296
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherHindawi Ltd
dc.relation.ispartofDisease Markersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleSoluble TNF-Like weak inducer of apoptosis as a new marker in preeclampsia: A pilot clinical study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Sumnu-Abdullah 2016.pdf
Boyut:
1.19 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu